Open AccessClinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation
Author(s) -
Ashley Vo,
Olivier Aubert,
Mark Haas,
Edmund Huang,
Xiaohai Zhang,
Jua Choi,
Alice Peng,
Reiad Najjar,
Supreet Sethi,
Noriko Ammerman,
Kathlyn Lim,
Stanley C. Jordan
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002691
Subject(s) - medicine , rituximab , transplantation , kidney transplantation , desensitization (medicine) , incidence (geometry) , donor specific antibodies , gastroenterology , biopsy , urology , renal function , clinical significance , tacrolimus , lymphoma , physics , receptor , optics
Highly HLA-sensitized (HS) patients have an increased risk for the development of donor-specific antibodies (DSA) and antibody-mediated rejection (AMR) posttransplant. Here, we examined the risk for AMR in HS patients transplanted after desensitization (DES) who were DSA+ versus DSA- at transplant. We also examined the incidence and clinical impact of de novo DSAs (dnDSAs) and compared with dnDSA- patients.